LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

Home・Aandelen Lijst・Cerus Corp

Cerus Corp

Open

SectorGezondheidszorg

2.44 4.72

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.33

Max

2.45

Belangrijke statistieken
By Trading Economics
Inkomsten	527K -1.6M
Verkoop	2.1M 60M
EPS	-0.01
Winstmarge	-2.752
Werknemers	261
EBITDA	1.9M 93K

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+92.31% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	108M 505M
Vorige openingsprijs	-2.28
Vorige sluitingsprijs	2.44

Nieuwssentiment

By Acuity

36%

64%

81 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

1.3 / 1.36 Steun & Weerstand

Cerus Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 mei 2026, 23:53 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 mei 2026, 22:47 UTC

Populaire aandelen

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mei 2026, 22:16 UTC

Acquisities, Fusies, Overnames

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mei 2026, 22:00 UTC

Belangrijke Marktbewegers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mei 2026, 18:09 UTC

Belangrijke Marktbewegers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 mei 2026, 23:50 UTC

Marktinformatie

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 mei 2026, 23:43 UTC

Marktinformatie

Global Equities Roundup: Market Talk

17 mei 2026, 23:43 UTC

Marktinformatie

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 mei 2026, 23:36 UTC

Marktinformatie

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 mei 2026, 23:07 UTC

Acquisities, Fusies, Overnames

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 mei 2026, 23:06 UTC

Acquisities, Fusies, Overnames

UOB: Share Sale Agreements Entered With Singland Properties

17 mei 2026, 23:05 UTC

Acquisities, Fusies, Overnames

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 mei 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 mei 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Acquire Stake for $389 Million

17 mei 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 mei 2026, 16:27 UTC

Acquisities, Fusies, Overnames

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mei 2026, 15:26 UTC

Acquisities, Fusies, Overnames

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 mei 2026, 08:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:59 UTC

Acquisities, Fusies, Overnames

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mei 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mei 2026, 21:16 UTC

Marktinformatie

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 mei 2026, 20:19 UTC

Populaire aandelen

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mei 2026, 19:41 UTC

Acquisities, Fusies, Overnames

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mei 2026, 19:35 UTC

Marktinformatie

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mei 2026, 19:33 UTC

Marktinformatie

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mei 2026, 18:35 UTC

Winsten

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Peer Vergelijking

Prijswijziging

Cerus Corp Prognose

Koersdoel

By TipRanks

92.31% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.5 USD 92.31%

Hoogste 5 USD

Laagste 4 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cerus Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Cerus Corp - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.3 / 1.36Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

81 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.